TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients

Inclusion Criteria: Male or female, age 18 years or older Documented HIV-1 infection Stable PI regimen for at least 8 weeks prior to screening Plasma viral load at screening above 1000 HIV-1 RNA copies/ml Prior use of more than 1 NRTI for at least 3 months Prior use of one or more NNRTIs as part of a failing regimen At least 1 primary PI mutation as defined by the IAS guidelines Treatment with at least 1 PI for a total of at least 3 months Patient has given informed consent Exclusion Criteria: Presence of any currently active AIDS defining illness except stable cutaneous Kaposi's Sarcoma and Wasting syndrome due to HIV infection Current or past history of alcohol and/or drug abuse which, in the investigator's opinion, would compromise the subject's safety or compliance to the study protocol procedures NNRTI as part of therapy at screening Patients on a treatment interruption at screening Patients for whom an investigational antiretroviral therapy is part of the regimen at screening or the use of any non-antiretroviral investigational agents 90 days prior to screening Hepatitis A, B, or C.